Literature DB >> 18831417

Eyelid neoplasms in the Beijing Tongren Eye Centre between 1997 and 2006.

Xiao Lin Xu1, Bin Li, Xian Li Sun, Liao Qing Li, Ruo Jin Ren, Fei Gao, Jost B Jonas.   

Abstract

BACKGROUND AND
OBJECTIVE: To examine the spectrum of eyelid neoplastic specimens obtained at the Beijing Tongren Eye Centre between 1997 and 2006. PATIENTS AND METHODS: A total of 2,639 eyelid neoplasms were included in the study.
RESULTS: Of the 2,639 eyelid specimens, 2,276 (86.2%) were benign and 363 (13.8%) were malignant. The most common benign lesions were inflammatory lesions, melanocytic nevi, papillomas, dermoid and epidermoid cysts, and epithelial cysts. The most common malignant or semi-malignant tumors were basal cell carcinomas, sebaceous gland carcinomas, lymphomas, squamous cell carcinomas, and malignant melanomas. The mean age at diagnosis was 41 years for benign lesions and 60 years for malignant tumors. There was no significant gender predilection among the five major non-benign eyelid tumors.
CONCLUSION: At the BeijingTongren Eye Centre between 1997 and 2006, the predominant non-benign eyelid tumors were basal cell carcinoma and sebaceous gland carcinoma, followed by lymphoma. The non-benign lesions occurred predominantly in elderly patients who were 60 years of age and older.

Entities:  

Mesh:

Year:  2008        PMID: 18831417     DOI: 10.3928/15428877-20080901-18

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  19 in total

Review 1.  Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.

Authors:  Sara C Shalin; Stephen Lyle; Eduardo Calonje; Alexander J F Lazar
Journal:  Histopathology       Date:  2010-01       Impact factor: 5.087

2.  Identifying predictive morphologic features of malignancy in eyelid lesions.

Authors:  Christina Leung; Davin Johnson; Renee Pang; Vladimir Kratky
Journal:  Can Fam Physician       Date:  2015-01       Impact factor: 3.275

3.  The practice patterns in the management of sebaceous carcinoma of the eyelid in the Asia Pacific region.

Authors:  Janice J C Cheung; Bita Esmaeli; Stacey C Lam; Tracey Kwok; Hunter K L Yuen
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

4.  A retrospective study of 2228 cases with eyelid tumors.

Authors:  Sha-Sha Yu; Yun Zhao; Hong Zhao; Jin-Yong Lin; Xin Tang
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

5.  Periocular sebaceous gland carcinoma: A comprehensive review.

Authors:  Kaustubh Mulay; Ekta Aggarwal; Valerie A White
Journal:  Saudi J Ophthalmol       Date:  2013-07

6.  Malignant Eyelid Tumors in India: A Study of 536 Asian Indian Patients.

Authors:  Swathi Kaliki; Nandini Bothra; Kavya Madhuri Bejjanki; Arpita Nayak; George Ramappa; Ashik Mohamed; Tarjani Vivek Dave; Mohammad Javed Ali; Milind N Naik
Journal:  Ocul Oncol Pathol       Date:  2018-09-13

7.  Eyelid Tumors at the University Eye Clinic of Ioannina, Greece: A 30-year Retrospective Study.

Authors:  Ioannis Asproudis; Georgios Sotiropoulos; Christos Gartzios; Vassilios Raggos; Alexandra Papoudou-Bai; Ioannis Ntountas; Andreas Katsanos; Athina Tatsioni
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Apr-Jun

8.  Tumors of the eye and ocular adnexa at the Philippine Eye Research Institute: a 10-year review.

Authors:  Rolando Enrique D Domingo; Lilibeth E Manganip; Rolando M Castro
Journal:  Clin Ophthalmol       Date:  2015-07-09

9.  Eyelid masses: a 10-year survey from a tertiary eye hospital in Tehran.

Authors:  Abbas Bagheri; Mehdi Tavakoli; Azadeh Kanaani; Reza Beheshti Zavareh; Hamed Esfandiari; Maryam Aletaha; Hossein Salour
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jul-Sep

10.  Comparison of the Clinical Characteristics and Outcome of Benign and Malignant Eyelid Tumors: An Analysis of 4521 Eyelid Tumors in a Tertiary Medical Center.

Authors:  Yu-Yun Huang; Wen-Yih Liang; Chieh-Chih Tsai; Shu-Ching Kao; Wei-Kuang Yu; Hui-Chuan Kau; Catherine Jui-Ling Liu
Journal:  Biomed Res Int       Date:  2015-11-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.